Pitavastatin

Generic Name: Pitavastatin

Brand Names: Livalo, Zypitamag

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₄FNO_₄

CAS Number: 147511-69-1

Unique Ingredient Identifier: M5681Q5F9P

Background: Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competiti...

Indication: 用于治疗高胆固醇症(高脂血症)、家族性高胆固醇症。

Associated Conditions: Apolipoprotein B increased, Elevation of serum triglyceride levels, Increases in serum total low-density lipoprotein (LDL), Increases in total cholesterol

Associated Therapies: -

Clinical Trials

China Protection Trial of Glucose Metabolism by Pitavastatin in Patients With Prediabetes and Hypertension

Phase 4

Conditions: Prediabetic State
Hypertension
Dyslipidemias

Interventions: Drug: Atorvastatin Calcium
Drug: Pitavastatin Calcium

First Posted Date: 2018-05-22

Last Posted Date: 2019-06-03

Lead Sponsor: Jun Tao

Target Recruit Count: 396

Registration Number: NCT03532620

Locations: 🇨🇳
First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
Fourth People's Hospital of Chongqing, Chongqing, Chongqing, China
🇨🇳
First Affiliated Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China

and more 10 locations

Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia

Phase 4

Conditions: Dyslipidemias

Interventions: Drug: Pitavastatin
Drug: Atorvastatin
Drug: Rosuvastatin

First Posted Date: 2018-02-01

Last Posted Date: 2018-02-01

Lead Sponsor: Fudan University

Target Recruit Count: 10000

Registration Number: NCT03418974

Locations: 🇨🇳
School of Public Health, Fudan University, Shanghai, Shanghai, China
🇨🇳
Heart Center of Peking University People's Hospital, Beijing, Beijing, China

PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)

Phase 3

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Pitavastatin
Drug: Placebos

First Posted Date: 2017-03-03

Last Posted Date: 2024-10-28

Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Target Recruit Count: 602

Registration Number: NCT03070223

Locations: 🇺🇸
Alabama CRS (31788), Birmingham, Alabama, United States
🇺🇸
University of Southern California (1201), Los Angeles, California, United States
🇺🇸
University of California, Los Angeles CARE Center CRS (601), Los Angeles, California, United States

and more 28 locations

Dyslipidemia of Obesity Intervention in Teens

Phase 3

Completed

Conditions: Dyslipidemia
Obesity

Interventions: Drug: Placebo
Drug: Pitavastatin

First Posted Date: 2016-11-06

Last Posted Date: 2024-07-05

Lead Sponsor: Carelon Research

Target Recruit Count: 122

Registration Number: NCT02956590

Locations: 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada

and more 13 locations

A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

Phase 1

Completed

Conditions: Influenza in Humans

Interventions: Drug: AL-794
Drug: Pitavastatin
Drug: JNJ-63623872
Drug: Digoxin
Drug: Oseltamivir
Drug: Midazolam

First Posted Date: 2016-09-05

Last Posted Date: 2018-06-25

Lead Sponsor: Alios Biopharma Inc.

Target Recruit Count: 68

Registration Number: NCT02888327

Locations: 🇬🇧
Hammersmith Medicines Research, London, United Kingdom

Effect of Pitavastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease

Phase 4

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Atorvastatin
Drug: Pitavastatin

First Posted Date: 2016-08-11

Last Posted Date: 2021-09-21

Lead Sponsor: Dong-A University

Target Recruit Count: 45

Registration Number: NCT02863185

Locations: 🇰🇷
Won Suk An, Busan, Korea, Republic of
🇰🇷
Dong-A University, Busan, Korea, Republic of

Drug Transporter Interaction Study PHENTRA_2015_KPUK

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: pitavastatin
Drug: Adefovir
Drug: digoxin
Drug: sitagliptin
Drug: Metformin

First Posted Date: 2016-04-19

Last Posted Date: 2019-09-10

Lead Sponsor: University of Cologne

Target Recruit Count: 24

Registration Number: NCT02743260

Locations: 🇩🇪
Department of Pharmacology I, University Hospital Cologne, Cologne, NRW, Germany

Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia

Phase 3

Withdrawn

Conditions: Hyperlipidemia
Dyslipidemia

Interventions: Drug: NK-104-CR
Drug: Placebo
Drug: Livalo

First Posted Date: 2016-02-01

Last Posted Date: 2021-05-10

Lead Sponsor: Kowa Research Institute, Inc.

Registration Number: NCT02670434

A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pitavastatin
Drug: JNJ-63623872

First Posted Date: 2015-11-03

Last Posted Date: 2016-01-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 14

Registration Number: NCT02595268

Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir

Phase 4

Completed

Conditions: HIV
Dyslipidemia

Interventions: Drug: pitavastatin
Drug: placebo

First Posted Date: 2015-05-13

Last Posted Date: 2016-10-10

Lead Sponsor: Ramathibodi Hospital

Target Recruit Count: 24

Registration Number: NCT02442700

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy